Ocular inflammatory events following COVID-19 vaccination: a multinational case series
Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of ophthalmic inflammation and infection - 12(2022), 1 vom: 04. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Testi, Ilaria [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
© The Author(s) 2021 |
|---|
| doi: |
10.1186/s12348-021-00275-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR045883211 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR045883211 | ||
| 003 | DE-627 | ||
| 005 | 20230519220136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12348-021-00275-x |2 doi | |
| 035 | |a (DE-627)SPR045883211 | ||
| 035 | |a (SPR)s12348-021-00275-x-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Testi, Ilaria |e verfasserin |0 (orcid)0000-0003-1711-033X |4 aut | |
| 245 | 1 | 0 | |a Ocular inflammatory events following COVID-19 vaccination: a multinational case series |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2021 | ||
| 520 | |a Background Inflammatory adverse events following COVID-19 vaccination are being reported amidst the growing concerns regarding vaccine’s immunogenicity and safety, especially in patients with pre-existing inflammatory conditions. Methods Multinational case series of patients diagnosed with an ocular inflammatory event within 14 days following COVID-19 vaccination collected from 40 centres over a 3 month period in 2021. Results Seventy patients presented with ocular inflammatory events within 14 days following COVID-19 vaccination. The mean age was 51 years (range, 19–84 years). The most common events were anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). The mean time to event was 5 days and 6 days (range, 1–14 days) after the first and second dose of vaccine, respectively. Among all patients, 36 (54.1%) had a previous history of ocular inflammatory event. Most patients (n = 48, 68.6%) were managed with topical corticosteroids. Final vision was not affected in 65 (92.9%), whereas 2 (2.9%) and 3 (4.3%) had reduction in visual acuity reduced by ≤3 lines and > 3 lines, respectively. Reported complications included nummular corneal lesions (n = 1, 1.4%), cystoid macular oedema (n = 2, 2.9%) and macular scarring (n = 2, 2.9%). Conclusion Ocular inflammatory events may occur after COVID-19 vaccination. The findings are based on a temporal association that does not prove causality. Even in the possibility of a causal association, most of the events were mild and had a good visual outcome. | ||
| 650 | 4 | |a Uveitis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Ocular inflammation |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immunomodulatory |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus disease |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Vaccination |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Brandão-de-Resende, Camilo |4 aut | |
| 700 | 1 | |a Agrawal, Rupesh |4 aut | |
| 700 | 1 | |a Pavesio, Carlos |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of ophthalmic inflammation and infection |d Berlin : Springer, 2011 |g 12(2022), 1 vom: 04. Jan. |w (DE-627)SPR024957690 |w (DE-600)2592309-2 |x 1869-5760 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:1 |g day:04 |g month:01 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s12348-021-00275-x |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 1 |b 04 |c 01 | ||